Structure-based computational screening of cyclotides as putative CYP19A1-binding scaffolds for modulation of estrogen biosynthesis in adenomyosis

Adenomyosis is a chronic estrogen-dependent gynecological disorder associated with dysmenorrhea, abnormal uterine bleeding, chronic pelvic pain, infertility, and recurrent implantation failure. Because human placental aromatase cytochrome P450 (CYP19A1) plays a central role in local estrogen biosynthesis, this study employed an integrated in silico workflow to identify cyclotide scaffolds capable of interacting with CYP19A1. The receptor structure was prepared and validated, while protein-protein interaction analysis confirmed its involvement in steroidogenesis and estrogen biosynthesis. Twenty cyclotides were modeled and screened against the predicted active site of CYP19A1. Based on an integrated evaluation of HADDOCK and ClusPro docking, binding orientation, and interaction characteristics, cycloviolacin O4 was prioritized as the lead candidate. The predicted CYP19A1-cycloviolacin O4 complex exhibited a HADDOCK score of -82.8 ± 9.8, a cluster RMSD of 0.2 ± 0.1 Å, and a ClusPro energy score of -872.1. Docking against the reference inhibitor exemestane and the reference peptide SNA-60-367-10 provided additional computational benchmarking. Subsequent 500 ns molecular dynamics simulations, normal mode analysis, and MM-GBSA/MM-PBSA calculations supported the predicted structural stability and dynamic compatibility of the complex, yielding binding free energies of -66.58 ± 3.46 kcal/mol (MM-GBSA) and -4.56 ± 4.29 kcal/mol (MM-PBSA). Computational safety assessment predicted cycloviolacin O4 to be non-antigenic, non-allergenic, and non-toxic, while immune simulation suggested a balanced immune response. Collectively, these findings identify cycloviolacin O4 as a computationally predicted CYP19A1-binding cyclotide scaffold. However, these observations are derived exclusively from computational analyses and require biochemical, cellular, and in vivo validation before any conclusions regarding biological activity or therapeutic potential can be drawn.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-17
DOI
https://doi.org/10.1371/journal.pone.0352405
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Structure-based computational screening of cyclotides as putative CYP19A1-binding scaffolds for modulation of estrogen biosynthesis in adenomyosis

Nouman Safdar Ali, Sibel Üstünel
3 links
PLoS ONE
Computational Drug Discovery Methods
article

Structure-based computational screening of cyclotides as putative CYP19A1-binding scaffolds for modulation of estrogen biosynthesis in adenomyosis

Nouman Safdar Ali, Sibel Üstünel
article en

Abstract

Adenomyosis is a chronic estrogen-dependent gynecological disorder associated with dysmenorrhea, abnormal uterine bleeding, chronic pelvic pain, infertility, and recurrent implantation failure. Because human placental aromatase cytochrome P450 (CYP19A1) plays a central role in local estrogen biosynthesis, this study employed an integrated in silico workflow to identify cyclotide scaffolds capable of interacting with CYP19A1. The receptor structure was prepared and validated, while protein-protein interaction analysis confirmed its involvement in steroidogenesis and estrogen biosynthesis. Twenty cyclotides were modeled and screened against the predicted active site of CYP19A1. Based on an integrated evaluation of HADDOCK and ClusPro docking, binding orientation, and interaction characteristics, cycloviolacin O4 was prioritized as the lead candidate. The predicted CYP19A1-cycloviolacin O4 complex exhibited a HADDOCK score of -82.8 ± 9.8, a cluster RMSD of 0.2 ± 0.1 Å, and a ClusPro energy score of -872.1. Docking against the reference inhibitor exemestane and the reference peptide SNA-60-367-10 provided additional computational benchmarking. Subsequent 500 ns molecular dynamics simulations, normal mode analysis, and MM-GBSA/MM-PBSA calculations supported the predicted structural stability and dynamic compatibility of the complex, yielding binding free energies of -66.58 ± 3.46 kcal/mol (MM-GBSA) and -4.56 ± 4.29 kcal/mol (MM-PBSA). Computational safety assessment predicted cycloviolacin O4 to be non-antigenic, non-allergenic, and non-toxic, while immune simulation suggested a balanced immune response. Collectively, these findings identify cycloviolacin O4 as a computationally predicted CYP19A1-binding cyclotide scaffold. However, these observations are derived exclusively from computational analyses and require biochemical, cellular, and in vivo validation before any conclusions regarding biological activity or therapeutic potential can be drawn.

PLoS ONEVol. 21(11)
Atlas Üniversitesi (TR)
Good health and well-being
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon